Should we focus on “venous vulnerability” instead of “plaque vulnerability” in symptomatic atherosclerotic patients?

Fabrizio Montecucco; François Mach

doi:10.1160/TH11-09-0655

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2011; 106(06): 995-996
DOI: 10.1160/TH11-09-0655

Invited Editorial Focus

Schattauer GmbH

Should we focus on “venous vulnerability” instead of “plaque vulnerability” in symptomatic atherosclerotic patients?

Fabrizio Montecucco

¹Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Geneva, Switzerland

,

François Mach

¹Division of Cardiology, Foundation for Medical Researches, Department of Medical Specialties, University of Geneva, Geneva, Switzerland

› Author Affiliations

Abstract

Full Text

References

References
1 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442
2 Naghavi M, Libby P, Falk E. et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-1672.
3 Montecucco F, Vuilleumier N, Pagano S. et al. Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 2011; 32: 412-421.
4 Ridker PM, Danielson E, Fonseca FA. et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.
5 Mirabelli-Badenier M, Braunersreuther V, Viviani GL. et al. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost 2011; 105: 409-420.
6 Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
7 Sørensen HT, Horvath-Puho E, Pedersen L. et al. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-1779.
8 Prandoni P, Bilora F, Marchiori A. et al. An association between atherosclerosis and venous thrombosis. N Engl J Med 2003; 348: 1435-1441.
9 Brouwer JL, Lijfering WM, Ten Kate MK. et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101: 93-99.
10 Lijfering WM, Coppens M, van de Poel MH. et al. The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98: 457-463.
11 Piazza G, Goldhaber S, Lessard D. et al. Venous Thromboembolism in patients with symptomatic atherosclerosis. Thromb Haemost 2011; 106: 1095-1102.
12 Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. Thromb Haemost 2008; 99: 995-1000.
13 Gresele P, Momi S, Migliacci R. Endothelium, venous thromboembolism and ischaemic cardiovascular events. Thromb Haemost 2010; 103: 56-61.
14 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
15 Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
16 Khemasuwan D, Chae YK, Gupta S. et al. Dose-related Effect of Statins in Venous Thrombosis Risk Reduction. Am J Med 2011; 124: 852-859.